BLLN (BillionToOne) Loans Receivable: $0.0 Mil (As of Mar. 2026)


BLLN BillionToOne Inc BLLN
13 GF Score
Price $122.33
! 5 Warning Signs
View Full Analysis

What is BillionToOne Loans Receivable?

BillionToOne BLLN +2.04% 13 Loans Receivable is $0.0 Mil as of Mar. 2026. GuruFocus rates BLLN with a GF Score™ of 13/100. The stock has 5 warning signs investors should review.

BillionToOne's Loans Receivable for the quarter that ended in Mar. 2026 was $0.0 Mil.

BillionToOne Loans Receivable Historical Data

* Premium members only.

The historical data trend for BillionToOne's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BillionToOne Loans Receivable Chart

BillionToOne Annual Data
Trend Dec23 Dec24 Dec25
Loans Receivable
0.00 0.00 0.00

BillionToOne Quarterly Data
Dec23 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Loans Receivable Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
BLLN
13GF Score
BillionToOne Inc BLLN
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BillionToOne Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of $0.0 Mil mean?
BillionToOne (BLLN) has a Loans Receivable of $0.0 Mil as of Mar. 2026. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on BillionToOne and its competitors.
Is BillionToOne's Loans Receivable too high?
BillionToOne's current Loans Receivable is $0.0 Mil. Overall, BillionToOne has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does BillionToOne's Loans Receivable compare to SHC and VCYT?
BillionToOne's Loans Receivable of $0.0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Medical Diagnostics & Research company?
A good Loans Receivable depends on the Medical Diagnostics & Research industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on BillionToOne and its competitors. BillionToOne's current Loans Receivable is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BillionToOne stock overvalued right now?
BillionToOne (BLLN) has a current Loans Receivable of $0.0 Mil. The current Loans Receivable is $0.0 Mil. BillionToOne's overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For BillionToOne (BLLN), the current Loans Receivable is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BillionToOne Business Description

Address 1035 O’Brien Drive, Menlo Park, CA, USA, 94025
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
13GF Score

Get the complete analysis for BLLN

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$122.33
Price